Government-Owned Inventions; Availability for Licensing, 24825-24826 [05-9395]
Download as PDF
<![CDATA[
24825
Federal Register / Vol. 70, No. 90 / Wednesday, May 11, 2005 / Notices
eligible networks will also be asked to
complete an additional more in-depth
survey (Tier 2).
Affected Public: Staff at clinical
research networks.
Type of Respondents: Staff
completing the surveys will include
physicians, nurses, administrators,
financial analysts, information
technology professionals, and clerks.
The annual reporting burden is as
follows:
ESTIMATES OF HOUR BURDEN AND ANNUALIZED COST TO RESPONDENTS
Type of
respondents
Number of
respondents
Frequency of
response
Average time
per response
Annual hour
burden
Hourly wage
rate
Respondent
cost
Core Survey
Principal Investigator/Physician ...............
240
1
.25
60
$470.00
$4,200.00
Extended Surveys
(1) Funding!:
Financial Managers ..........................
(2) Focus! Scientific Productivity, Management, and Governance:
Principal Investigator! Physician .......
(3) Network Operations and Training:
Study Coordinator! Registered Nurse
(4) Recruitment and Retention:
Study Coordinator! Registered Nurse
(5) Information Technology (IT) and Data
Management:
Network and Database Administrators ................................................
100
VerDate jul<14>2003
16:48 May 10, 2005
Jkt 205001
.75
75
38.00
2,850.00
100
1
1.25
125
70.00
8,750.00
100
1
1.25
125
25.00
3,125.00
100
1
.50
50
25.00
1,250.00
100
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies should
address one or more of the following
points: (1) Whether the proposed
collection of information is necessary
for the proper performance of the
function of the agency, including
whether the information will have
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
Ways to enhance the quality, utility, and
clarity of the information to be
collected; and (4) Ways to minimize the
burden of the collection of information
on those who are to respond, including
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology.
Direct Comments to OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice
should be directed to the Office of
Management and Budget, Office of
Regulatory Affairs, New Executive
Office Building, Room 10235,
Washington, DC 20502, Attention: NIH
Desk Officer. To request more
information on the proposed project or
to obtain a copy of data collection plans
and instruments, contact Dr. Paul Sorlie,
Division of Epidemiology and Clinical
Applications, NHLBI, NIH, II Rockledge
Centre, 6701 Rockledge Drive, MSC
#7934, Bethesda, MD 20892–7934, or
1
1
1.0
100
29.00
2,900.00
call non-toll-free number (301) 435–
0707, or e-mail your request, including
your address to: sorliep@nhlbi.nih.gov.
Comments Due Date: Comments
regarding this information collected are
best assured of having their full effect if
received within 30-days of the date of
this publication.
Dated: May 4, 2005.
Charles Mackay,
Chief, Project Clearance Liaison, National
Institutes of Health.
[FR Doc. 05–9393 Filed 5–10–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, DHHS.
AGENCY:
ACTION:
Notice.
SUMMARY: The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent application
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: (301)
496–7057; fax: (301) 402–0220. A signed
Confidential Disclosure Agreement will
be required to receive a copy of the
patent application.
Preparation and Use of Androgenic
Compounds: Nandrolone 17betacarbonates
Richard P. Blye and Hyun K. Kim
(NICHD)
U.S. Provisional Application No. 60/
650,376 filed 04 Feb 2005 (DHHS
Reference No. E–181–2004/0–US–01)
Licensing Contact: Marlene Shinn-Astor;
301/435–4426; shinnm@mail.nih.gov.
Hypogonadism is defined as deficient
or absent male gonadal function that
results in insufficient testosterone
secretion. Hypogonadism can be caused
by surgery; radiation; genetic and
developmental disorders; liver and
kidney disease; infection; and certain
auto-immune disorders. The most
common genetic disorders are
Klinefelter syndrome found in men and
Turner syndrome in women.
Hypogonadism affects an estimated 4
to 5 million men in the United States,
and although it may occur in men at any
E:\FR\FM\11MYN1.SGM
11MYN1
24826
Federal Register / Vol. 70, No. 90 / Wednesday, May 11, 2005 / Notices
age, low testosterone levels are
especially common in older males. More
than 60% of men over age 65 have free
testosterone levels below the normal
values of men aged 30 to 35. Studies
suggest that hypogonadism in adult men
is often underdiagnosed and under
treated. This may be because the
symptoms are easily attributed to aging
or other medical causes, or ignored by
patients and physicians. In fact, only
about 5% of hypogonadal men receive
testosterone replacement. Some experts
also believe that we need to reevaluate
normal testosterone levels and lower the
diagnostic cutoff for hypogonadism. By
doing so, many patients who we now
consider to be ‘‘low-normal’’ would
probably be considered candidates for
androgen replacement.
The inventors have discovered
androgenic compounds, the lead
compound being 17beta-carbonates of
nandrolone derivatives. These
compounds can be used to treat
hypogonadism, as hormonal therapy
and as a male contraceptive. The
disclosed carbonates have potent
activity when administered as an oral
composition. In addition, long-lasting
activity has also been observed with
subcutaneous administration in
laboratory animals. It is foreseen that
these androgens can be utilized in
hormonal replacement therapy for both
men and women, which constitute a
huge market both in the United States
and abroad.
Dated: May 4, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 05–9395 Filed 5–10–05; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Fogarty International Center; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
Fogarty International Center Advisory
Board.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
VerDate jul<14>2003
16:48 May 10, 2005
Jkt 205001
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Fogarty International
Center Advisory Board.
Date: May 23–24, 2005.
Closed: May 23, 2005, 1:30 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: National Institutes of Health,
Lawton Chiles International House, Bethesda,
MD 20892.
Open: May 24, 2005, 8:30 a.m. to
Adjournment.
Agenda: A Report of the FIC Director on
updates and overviews of new FIC initiatives.
Topics to be discussed: The Internet:
Globalization of Health Research in the 21st
Century.
Place: National Institutes of Health,
Lawton Chiles International House, Bethesda,
MD 20892.
Contact Person: Jean L. Flagg-Newton,
PhD, Special Assistant to the Director, FIC,
Fogarty International Center, National
Institutes of Health, 9000 Rockville Pike,
Building 31, Room B2C29, Bethesda, MD
20892, (301) 496–2968,
flaggnej@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s Home page: https://
www.nih.gov/fic/about/advisory.html, where
an agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.106, Minority International
Research Training Grant in the Biomedical
and Behavioral Sciences; 93.154, Special
International Postdoctoral Research Program
in Acquired Immunodeficiency Syndrome;
93.168, International Cooperative
Biodiversity Groups Program; 93.934, Fogarty
International Research Collaboration Award;
93.989, Senior International Fellowship
Awards Program, National Institutes of
Health, HHS)
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
Dated: May 4, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–9363 Filed 5–10–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (U.S.C. Appendix 2), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel, NCI
Transition Career Development Award PAR–
04–040.
Date: May 18, 2005.
Time: 11 a.m. to 12 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6116
Executive Boulevard, Rockville, MD 20852,
(Telephone Conference Call).
Contact Person: Robert Bird, PhD,
Scientific Review Administrator, Resources
and Training Review Branch, National
Cancer Institute, National Institutes of
Health, 6116 Executive Blvd., Room 8113,
MSC 8328, Bethesda, MD 20892–8328, 301–
496–7978, birdr@mail.nih.gov.
This notice is being published less than 15
days prior to meeting due to scheduling
conflicts.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: May 4, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–9360 Filed 5–10–05; 8:45 am]
BILLING CODE 4140–01–M
E:\FR\FM\11MYN1.SGM
11MYN1
]]>Agencies
[Federal Register Volume 70, Number 90 (Wednesday, May 11, 2005)]
[Notices]
[Pages 24825-24826]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-9395]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
application listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: (301) 496-7057; fax: (301) 402-0220. A
signed Confidential Disclosure Agreement will be required to receive a
copy of the patent application.
Preparation and Use of Androgenic Compounds: Nandrolone 17beta-
carbonates
Richard P. Blye and Hyun K. Kim (NICHD)
U.S. Provisional Application No. 60/650,376 filed 04 Feb 2005 (DHHS
Reference No. E-181-2004/0-US-01)
Licensing Contact: Marlene Shinn-Astor; 301/435-4426;
shinnm@mail.nih.gov.
Hypogonadism is defined as deficient or absent male gonadal
function that results in insufficient testosterone secretion.
Hypogonadism can be caused by surgery; radiation; genetic and
developmental disorders; liver and kidney disease; infection; and
certain auto-immune disorders. The most common genetic disorders are
Klinefelter syndrome found in men and Turner syndrome in women.
Hypogonadism affects an estimated 4 to 5 million men in the United
States, and although it may occur in men at any
[[Page 24826]]
age, low testosterone levels are especially common in older males. More
than 60% of men over age 65 have free testosterone levels below the
normal values of men aged 30 to 35. Studies suggest that hypogonadism
in adult men is often underdiagnosed and under treated. This may be
because the symptoms are easily attributed to aging or other medical
causes, or ignored by patients and physicians. In fact, only about 5%
of hypogonadal men receive testosterone replacement. Some experts also
believe that we need to reevaluate normal testosterone levels and lower
the diagnostic cutoff for hypogonadism. By doing so, many patients who
we now consider to be ``low-normal'' would probably be considered
candidates for androgen replacement.
The inventors have discovered androgenic compounds, the lead
compound being 17beta-carbonates of nandrolone derivatives. These
compounds can be used to treat hypogonadism, as hormonal therapy and as
a male contraceptive. The disclosed carbonates have potent activity
when administered as an oral composition. In addition, long-lasting
activity has also been observed with subcutaneous administration in
laboratory animals. It is foreseen that these androgens can be utilized
in hormonal replacement therapy for both men and women, which
constitute a huge market both in the United States and abroad.
Dated: May 4, 2005.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 05-9395 Filed 5-10-05; 8:45 am]
BILLING CODE 4140-01-P
